Navigation Links
Centrix Pharmaceutical Announces Clofera(TM), a Unique Antitussive and Nasal Decongestant for the Temporary Relief of Cough and Nasal Congestion
Date:8/14/2009

BIRMINGHAM, Ala., Aug. 14 /PRNewswire/ -- Centrix Pharmaceutical, Inc., a privately-held specialty pharmaceutical company focused on Pediatrics and Women's Health, announced plans to commercially launch Clofera(TM) for the temporary relief of cough and nasal congestion.

Clofera(TM) is indicated for the temporary relief of cough and nasal congestion due to the common cold, hay fever, or other upper respiratory allergies. Clofera(TM) contains a non-narcotic antitussive, chlophedianol hydrochloride, in addition to nasal decongestant, pseudoephedrine hydrochloride. The product is specifically formulated without dyes, sugar, alcohol or gluten to meet particular consumer needs and address patient sensitivities. Clofera(TM) is expected to release during the beginning of the fourth quarter.

"We are pleased to introduce Clofera to temporarily control the cough reflex, therefore reducing the intensity of coughing with a product that is free of narcotic effects. Clofera provides physicians with another therapeutic option in the management of cough and congestion associated with allergic rhinitis or the common cold. The release of Clofera further compliments our goal to develop and expand the Centrix specialty portfolio," stated John R. (Bob) Booth, President and CEO of Centrix Pharmaceutical.

About Clofera(TM)

Clofera(TM) temporarily controls the cough reflex, temporarily relieves nasal congestion, swollen nasal passages, sinus congestion and pressure. Clofera(TM) should not be used in patients taking monoamine oxidase inhibitors or with known hypersensitivity to any of the components of the product. Patients with a chronic cough, asthma, emphysema, mucus production, heart disease, high blood pressure, thyroid disease, diabetes, or enlarged prostate should consult physician before use. Recommended dosage should not be exceeded. Clofera(TM) contains no dextromethorphan, antihistamines, sugar, alcohol, or dyes and is gluten free. Clofera(TM) will be available in grape flavor.

About Centrix Pharmaceutical, Inc.

Centrix Pharmaceutical is a privately-held specialty pharmaceutical company focused in Pediatrics and Women's Health. Headquartered in Birmingham, AL, the Company's products are marketed by its dedicated sales force in the United States. For more information about Centrix Pharmaceutical, Inc. visit www.cenrx.com.


'/>"/>
SOURCE Centrix Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CareCentrix Adds to Senior Leadership Team
2. HeartCentrix Informatics Solution from Cardiac Science Now Certified with Allscripts Electronic Health Records
3. Gentiva(R) Health Services Promotes Boelsen to Senior Vice President, CareCentrix(R)
4. Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Henry Schein Medical Systems MicroMD(R) EMR 5.0
5. Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies
6. WuXi PharmaTech Selected as One of the Top Ten Employer for New College Graduates in Pharmaceutical Industry in 2009
7. Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals
8. Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
9. Thomson Reuters Invites You to the First Latin American Forum Covering the Pharmaceutical Industry
10. Sun Pharmaceutical to File HSR Application for Taro Tender Offer
11. Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
Breaking Medicine Technology: